Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT07833085
Recruiting Not applicable

CAIX-targeted PET/CT in Solid Tumors

NCT07833085 · tracked via the Priya Life Science China tracker
Sponsor
Zhongnan Hospital
Phase
Not applicable
Started
2026-09-21
Last updated
2026-10-13

Condition(s) studied

Malignant Solid TumorsClear Cell Renal Cell CarcinomaLung Cancer (NSCLC)Breast Cancer

Investigational drug(s) / intervention(s)

68Ga-CAIX

68Ga-CAIX: The subjects receive a PET/CT scan 30-60 minutes after intravenous administration of 68Ga-CAIX

Study summary

Tumor hypoxic microenvironment plays an important role in the initiation and progression of solid tumors, as well as tumor invasion, metastasis, and treatment resistance. Carbonic anhydrase IX (CAIX), as a crucial downstream molecule regulated by hypoxia-inducible factor-1 (HIF-1), is highly expressed in various solid tumors and is closely associated with tumor invasiveness, treatment response, and prognosis; thus, it represents an ideal target for tumor diagnosis and therapy. This study aims to explore the diagnostic value of CAIX-targeted PET/CT imaging in various solid tumors, as well as the correlation between tumor uptake and tissue CAIX expression.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Participants with suspected malignant solid tumors or patients with newly diagnosed or recurrent/metastatic malignant solid tumors confirmed by histopathology; * Age of 18 years and above, both male and female are eligible; * The ECOG PS score for physical condition in the Eastern Cancer Collaboration Group is 0-1 points; * Research participants voluntarily sign informed consent forms or have their parents/children/legal guardians sign informed consent forms, and are able to complete the trial according to the requirements of the research protocol. Exclusion Criteria: * Participants with severe liver and kidney dysfunction and cardiac dysfunction; * Participants with severe obesity, claustrophobia, or other reasons who are unable to undergo PET scans; * Pregnant or lactating women; * Other situations that researchers believe should be excluded and documented.

Primary outcome measure(s)

  • Evaluation of diagnostic performance — up to 6 months
    To evaluate the diagnostic efficacy of ⁶⁸Ga-CAIX PET/CT imaging in detecting primary and metastatic lesions of malignant solid tumors.

Trial sites (1)

FacilityCityRegionStatus
Zhongnan hospital of Wuhan University Wuhan Hubei Recruiting

More Zhongnan Hospital trials in China

CXCR4-targeted PET/CT Imaging in Hematological Malignancies Recruiting
Evaluation of the Diagnostic Efficacy of a αvβ6/FAP-Targeting Heterodimeric Probe in Patients With Malignant Solid Tumors Starting soon
Cadonilimab Plus Anlotinib for R/M/P Cervical Cancer Recruiting
A Study on the Effect of Medical Students' Literature Reading Patterns on Cognitive Load and Academic Writing Ability Recruiting
Effect of Adding Electroacupuncture to Anti-cancer Therapy-induced Peripheral Neuropathy Recruiting

Other trials for the same condition

Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure Recruiting
A Study of BL-M17D1 in Patients With Locally Advanced or Metastatic HER2 Positive/Negative Breast Cancer and Other Solid Tumors Recruiting
Sub-topic Four: Clinical Translation of Original Radioactive Drugs for Precision Diagnosis and Treatment of Gastrointestinal Tumors -Clinical Application Value of PET Imaging Targeting LRRC15 in Malignant Tumors Recruiting
Application of EndoScell Intraoperative Cellular Probing Technology for Early-Stage Breast Cancer Recruiting
Treatment of Breast Cancer With Trastuzumab + HS627/ Pertuzumab + Docetaxel Active, not recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07833085 on ClinicalTrials.gov ↗ ← All trials in China